tiprankstipranks
Trending News
More News >
Penumbra (PEN)
NYSE:PEN
US Market

Penumbra (PEN) Stock Forecast & Price Target

Compare
427 Followers
See the Price Targets and Ratings of:

PEN Analyst Ratings

Strong Buy
16Ratings
Strong Buy
12 Buy
4 Hold
0 Sell
Based on 16 analysts giving stock ratings to
Penumbra
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PEN Stock 12 Month Forecast

Average Price Target

$319.58
▲(23.44%Upside)
Based on 16 Wall Street analysts offering 12 month price targets for Penumbra in the last 3 months. The average price target is $319.58 with a high forecast of $340.00 and a low forecast of $260.00. The average price target represents a 23.44% change from the last price of $258.90.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"170":"$170","341":"$341","212.75":"$212.8","255.5":"$255.5","298.25":"$298.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":340,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$340.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":319.58,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$319.58</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":260,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$260.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[170,212.75,255.5,298.25,341],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,256.16,262.6092307692308,269.0584615384616,275.5076923076923,281.9569230769231,288.40615384615387,294.85538461538465,301.3046153846154,307.75384615384615,314.20307692307694,320.6523076923077,327.10153846153844,333.5507692307692,{"y":340,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,256.16,261.03846153846155,265.91692307692307,270.79538461538465,275.67384615384617,280.5523076923077,285.4307692307692,290.3092307692308,295.1876923076923,300.06615384615384,304.94461538461536,309.82307692307694,314.70153846153846,{"y":319.58,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,256.16,256.4553846153846,256.75076923076927,257.04615384615386,257.3415384615385,257.6369230769231,257.9323076923077,258.22769230769234,258.5230769230769,258.8184615384615,259.11384615384617,259.40923076923076,259.7046153846154,{"y":260,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":189.47,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":177.09,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":171.25,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":202.32,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":191.56,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":233.3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":244.84,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":237.48,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":266.97,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":285.44,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":271.13,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":291.82,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":256.16,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$340.00Average Price Target$319.58Lowest Price Target$260.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on PEN
TipRanks AITipRanks
Not Ranked
TipRanks
$303
Buy
17.03%
Upside
Reiterated
05/16/25
Penumbra's overall stock score reflects strong financial performance with notable revenue and margin growth, primarily driven by its U.S. thrombectomy business. However, the high P/E ratio suggests potential overvaluation, and short-term technical indicators point to possible weakness. The earnings call provided positive growth insights but also highlighted challenges in international markets. These factors collectively contribute to a balanced overall score.
William Blair Analyst forecast on PEN
Margaret KaczorWilliam Blair
William Blair
Buy
Reiterated
06/04/25
Penumbra: Strong Market Position and Growth Potential Drive Buy Rating
Wells Fargo Analyst forecast on PEN
Larry BiegelsenWells Fargo
Wells Fargo
$315
Buy
21.67%
Upside
Reiterated
05/29/25
Penumbra's Growth Potential Boosted by STORM-PE Trial and Thunderbolt Device Innovations
William O'Neil Analyst forecast on PEN
Rajan GuptaWilliam O'Neil
Not Ranked
William O'Neil
Hold
Downgraded
05/29/25
William ONeil downgrades Penumbra (PEN) to HoldWilliam ONeil analyst Raj Gupta downgraded Penumbra (NYSE: PEN) from Buy to Hold.
Citi
$320
Hold
23.60%
Upside
Reiterated
05/22/25
Penumbra (PEN) Gets a Hold from Citi
Bank of America Securities Analyst forecast on PEN
Travis SteedBank of America Securities
Bank of America Securities
$320
Buy
23.60%
Upside
Reiterated
05/15/25
Penumbra's Strategic Positioning and Growth Potential Justify Buy Rating
Piper Sandler Analyst forecast on PEN
Matthew O'BrienPiper Sandler
Piper Sandler
$330
Buy
27.46%
Upside
Reiterated
05/09/25
Penumbra (PEN) Receives a Buy from Piper Sandler
Truist Financial Analyst forecast on PEN
Richard NewitterTruist Financial
Truist Financial
Buy
Reiterated
04/24/25
Analysts Conflicted on These Healthcare Names: Amedisys (NASDAQ: AMED), Siemens Healthineers AG (Other OTC: SEMHF) and Penumbra (NYSE: PEN)
Leerink Partners Analyst forecast on PEN
Mike KratkyLeerink Partners
Leerink Partners
$313$327
Buy
26.30%
Upside
Reiterated
04/24/25
Penumbra's Strong Growth Potential and Strategic U.S. Focus Earns 'Buy' Rating
Stifel Nicolaus Analyst forecast on PEN
Mathew BlackmanStifel Nicolaus
Stifel Nicolaus
$301$318
Buy
22.83%
Upside
Reiterated
04/24/25
Penumbra price target raised to $318 from $301 at StifelPenumbra price target raised to $318 from $301 at Stifel
Robert W. Baird Analyst forecast on PEN
David RescottRobert W. Baird
Robert W. Baird
$316$325
Buy
25.53%
Upside
Reiterated
04/24/25
Penumbra price target raised to $325 from $316 at BairdPenumbra price target raised to $325 from $316 at Baird
Canaccord Genuity Analyst forecast on PEN
William PlovanicCanaccord Genuity
Canaccord Genuity
$340
Buy
31.32%
Upside
Reiterated
04/24/25
Penumbra's Strong Q1 Performance and Strategic Positioning Justify Buy Rating Despite Conservative FY25 Guidance
Morgan Stanley Analyst forecast on PEN
Kallum TitchmarshMorgan Stanley
Morgan Stanley
$260
Hold
0.42%
Upside
Reiterated
04/24/25
Analysts Offer Insights on Healthcare Companies: Astellas Pharma (Other OTC: ALPMF), Penumbra (NYSE: PEN) and Genmab (NASDAQ: GMAB)
UBS
$320$330
Buy
27.46%
Upside
Reiterated
04/24/25
Penumbra price target raised to $330 from $320 at UBSPenumbra price target raised to $330 from $320 at UBS
BTIG
$305$320
Buy
23.60%
Upside
Reiterated
04/24/25
Penumbra price target raised to $320 from $305 at BTIGPenumbra price target raised to $320 from $305 at BTIG
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on PEN
TipRanks AITipRanks
Not Ranked
TipRanks
$303
Buy
17.03%
Upside
Reiterated
05/16/25
Penumbra's overall stock score reflects strong financial performance with notable revenue and margin growth, primarily driven by its U.S. thrombectomy business. However, the high P/E ratio suggests potential overvaluation, and short-term technical indicators point to possible weakness. The earnings call provided positive growth insights but also highlighted challenges in international markets. These factors collectively contribute to a balanced overall score.
William Blair Analyst forecast on PEN
Margaret KaczorWilliam Blair
William Blair
Buy
Reiterated
06/04/25
Penumbra: Strong Market Position and Growth Potential Drive Buy Rating
Wells Fargo Analyst forecast on PEN
Larry BiegelsenWells Fargo
Wells Fargo
$315
Buy
21.67%
Upside
Reiterated
05/29/25
Penumbra's Growth Potential Boosted by STORM-PE Trial and Thunderbolt Device Innovations
William O'Neil Analyst forecast on PEN
Rajan GuptaWilliam O'Neil
Not Ranked
William O'Neil
Hold
Downgraded
05/29/25
William ONeil downgrades Penumbra (PEN) to HoldWilliam ONeil analyst Raj Gupta downgraded Penumbra (NYSE: PEN) from Buy to Hold.
Citi
$320
Hold
23.60%
Upside
Reiterated
05/22/25
Penumbra (PEN) Gets a Hold from Citi
Bank of America Securities Analyst forecast on PEN
Travis SteedBank of America Securities
Bank of America Securities
$320
Buy
23.60%
Upside
Reiterated
05/15/25
Penumbra's Strategic Positioning and Growth Potential Justify Buy Rating
Piper Sandler Analyst forecast on PEN
Matthew O'BrienPiper Sandler
Piper Sandler
$330
Buy
27.46%
Upside
Reiterated
05/09/25
Penumbra (PEN) Receives a Buy from Piper Sandler
Truist Financial Analyst forecast on PEN
Richard NewitterTruist Financial
Truist Financial
Buy
Reiterated
04/24/25
Analysts Conflicted on These Healthcare Names: Amedisys (NASDAQ: AMED), Siemens Healthineers AG (Other OTC: SEMHF) and Penumbra (NYSE: PEN)
Leerink Partners Analyst forecast on PEN
Mike KratkyLeerink Partners
Leerink Partners
$313$327
Buy
26.30%
Upside
Reiterated
04/24/25
Penumbra's Strong Growth Potential and Strategic U.S. Focus Earns 'Buy' Rating
Stifel Nicolaus Analyst forecast on PEN
Mathew BlackmanStifel Nicolaus
Stifel Nicolaus
$301$318
Buy
22.83%
Upside
Reiterated
04/24/25
Penumbra price target raised to $318 from $301 at StifelPenumbra price target raised to $318 from $301 at Stifel
Robert W. Baird Analyst forecast on PEN
David RescottRobert W. Baird
Robert W. Baird
$316$325
Buy
25.53%
Upside
Reiterated
04/24/25
Penumbra price target raised to $325 from $316 at BairdPenumbra price target raised to $325 from $316 at Baird
Canaccord Genuity Analyst forecast on PEN
William PlovanicCanaccord Genuity
Canaccord Genuity
$340
Buy
31.32%
Upside
Reiterated
04/24/25
Penumbra's Strong Q1 Performance and Strategic Positioning Justify Buy Rating Despite Conservative FY25 Guidance
Morgan Stanley Analyst forecast on PEN
Kallum TitchmarshMorgan Stanley
Morgan Stanley
$260
Hold
0.42%
Upside
Reiterated
04/24/25
Analysts Offer Insights on Healthcare Companies: Astellas Pharma (Other OTC: ALPMF), Penumbra (NYSE: PEN) and Genmab (NASDAQ: GMAB)
UBS
$320$330
Buy
27.46%
Upside
Reiterated
04/24/25
Penumbra price target raised to $330 from $320 at UBSPenumbra price target raised to $330 from $320 at UBS
BTIG
$305$320
Buy
23.60%
Upside
Reiterated
04/24/25
Penumbra price target raised to $320 from $305 at BTIGPenumbra price target raised to $320 from $305 at BTIG
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Penumbra

1 Month
xxx
Success Rate
14/20 ratings generated profit
70%
Average Return
+6.64%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 70.00% of your transactions generating a profit, with an average return of +6.64% per trade.
3 Months
xxx
Success Rate
21/35 ratings generated profit
60%
Average Return
+3.32%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +3.32% per trade.
1 Year
Richard NewitterTruist Financial
Success Rate
10/15 ratings generated profit
67%
Average Return
+2.24%
reiterated a buy rating 2 months ago
Copying Richard Newitter's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +2.24% per trade.
2 Years
xxx
Success Rate
16/22 ratings generated profit
73%
Average Return
+11.84%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 72.73% of your transactions generating a profit, with an average return of +11.84% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PEN Analyst Recommendation Trends

Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
0
0
0
0
0
Buy
20
16
28
20
20
Hold
6
5
7
6
5
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
26
21
35
26
25
In the current month, PEN has received 20 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. PEN average Analyst price target in the past 3 months is 319.58.
Each month's total comprises the sum of three months' worth of ratings.

PEN Financial Forecast

PEN Earnings Forecast

Next quarter’s earnings estimate for PEN is $0.82 with a range of $0.71 to $0.90. The previous quarter’s EPS was $0.83. PEN beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year PEN has Outperformed its overall industry.
Next quarter’s earnings estimate for PEN is $0.82 with a range of $0.71 to $0.90. The previous quarter’s EPS was $0.83. PEN beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year PEN has Outperformed its overall industry.

PEN Sales Forecast

Next quarter’s sales forecast for PEN is $327.75M with a range of $325.50M to $334.00M. The previous quarter’s sales results were $324.14M. PEN beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.54% of the time in the same period. In the last calendar year PEN has Outperformed its overall industry.
Next quarter’s sales forecast for PEN is $327.75M with a range of $325.50M to $334.00M. The previous quarter’s sales results were $324.14M. PEN beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.54% of the time in the same period. In the last calendar year PEN has Outperformed its overall industry.

PEN Stock Forecast FAQ

What is PEN’s average 12-month price target, according to analysts?
Based on analyst ratings, Penumbra’s 12-month average price target is 319.58.
    What is PEN’s upside potential, based on the analysts’ average price target?
    Penumbra has 23.44% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is PEN a Buy, Sell or Hold?
          Penumbra has a consensus rating of Strong Buy which is based on 12 buy ratings, 4 hold ratings and 0 sell ratings.
            What is Penumbra’s price target?
            The average price target for Penumbra is 319.58. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $340.00 ,the lowest forecast is $260.00. The average price target represents 23.44% Increase from the current price of $258.9.
              What do analysts say about Penumbra?
              Penumbra’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.
                How can I buy shares of PEN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis